Pharmacy

Your Article Summary

See Latest Articles

Novel evidence-based systemic lupus erythematosus (sle) responder index described in peer reviewed publication as potentially significant advance in lupus drug development
Human Genome Sciences, 09/08/09

Human Genome Sciences, Inc. announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence–based systemic lupus erythematosus Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in serologically active patients with SLE. This primary endpoint was accepted by the FDA under a Special Protocol Assessment agreement for the Phase 3 trials.

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis, 03/19/10

Medtronic Receives FDA Approval for Industrys Most Advanced Integrated System for Diabetes Management
Medtronic, 03/18/10

Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis
Current Osteoporosis Reports, 03/18/10

 See all of Drug Approvals

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia
Medtronic, 03/19/10

FDA Advisory Panel Unanimously Recommends Expanded Indication for Boston Scientifics Heart Failure Devices Based on Landmark MADIT-CRT Trial
Boston Scientific, 03/19/10

Human genome sciences announces results of randomized phase 2 trial of mapatumumab in non-small cell lung cancer
Human Genome Sciences, 03/18/10

 See all of Drug Trials